The Benchmark Company rated the Neurocrine Biosciences Inc. (NASDAQ: NBIX) stock “a Hold”. The Benchmark Company’s estimates were contained in a research note released on Wednesday, September 30, 2020. Several other experts on Wall Street have posted such reports regarding the NBIX shares.According to JP Morgan, the stock is “a Neutral,” and set its price target at $136. JP Morgan published their figures in a research note released to investors on Tuesday, August 04, 2020. Other experts at Goldman have the stock’s price target at $135 price; with their rating of the stock is “a Neutral.” These scores were published in a research note the firm released on Monday, June 29, 2020.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Wall Street analysts tracking the Neurocrine Biosciences Inc. (NASDAQ: NBIX) stock on daily basis. Out of 25 analysts, 15 deeming the stock a Buy and 1 gave it a rating of OVERWEIGHT. Another 9 recommended that NBIX is a HOLD, while 0 rated it UNDERWEIGHT and the same number recommended SELL. If we look at the broader picture, the above ratings give the stock an average analyst rating of 2.00.
Neurocrine Biosciences Inc. has a market valuation of $9.27 billion and last released its earnings reports on 02/16/2021, for the quarterly period ended on 9/29/2020. The company’s revenue for the quarter stood at $258.5 billion. NBIX Company also reported its earnings per share (EPS) as -$0.62 for the quarter, which miss consensus estimates by analysts of $0.22 by -$0.84, surprisingly -381.80% lower.
The stock market has more often than not ended up being extremely baffling, catching even some of the more experienced traders by surprise. It happens that even when results are as projected, the market sometimes just takes a sudden turn towards the opposite direction. Often such events lead to doubt and much speculation. At such time, it may pay to keep tabs on a stock’s historical price performance. Useful also would be knowledge of the stock’s trends, both the short term and long-term. Neurocrine Biosciences Inc. (NASDAQ: NBIX) share prices have increased by 10.98% over the past week, but are up 6.72% over prices posted in the last quarter. Going further back, the stock’s price has gone over -19.98% over the last 6 months but is up 12.83% in year-to-date trading.
A recent spot check on the stock’s support and resistance revealed that the publicly-traded Neurocrine Biosciences Inc. (NASDAQ: NBIX) shares are trading at a price close to -4.63% lower than its 90-day high. On the other hand, the stock is +25.73% away from its low in the 90-day period. More broadly, NBIX’s current price is -20.63% away from 52-week high. The price is 49.92% above from its 52-week low.
For regular shareholders interested in finding out how worthwhile it would be to invest in the company, then note that Neurocrine Biosciences Inc. has an ROE of 12.60%. An analysis will help understand that the lower the ROE figure; the worse a company is when it comes to generating profits. The term Return on Assets (ROA) is a ratio that points to a businesses’ profitability relative to overall assets. The company under our focus has a current ROA of 6.60%. If a business manages its assets well, then the ROA will be higher. However, the opposite will be true (lower returns) if that business is shown to be poor managers of their assets. A look at another ratio shows that Neurocrine Biosciences Inc. has a Return on Investment (ROI) of 6.00%. When profits exceed costs, then the ROI percentage will be positive, and analysts will rate such business as having a net gain. However, if the percentage index is negative, then the company’s costs basically outweigh profits.
Focusing on the company’s market volatility shows that it has a 1-Week Volatility index of 5.92%, and 3.84% for the month. This stock’s Average True Range (ATR) currently stands at 4.06, with the beta factor poised at 0.89. The indicator of Volatility helps exhibit the extent to which a stock is likely to plummet or climb when the rest of the market also dips or surges. If a stock has a beta score above 1, then its rate of volatility is high. Figures lower than 1, therefore, means that the stock’s volatility at that particular moment is low.
Shares of the Neurocrine Biosciences Inc. (NASDAQ: NBIX) dropped by -$4.17 during Wednesday’s regular trading session to climb to $108.15. The company had a daily trading volume of 1.54 million shares, higher than its average intra-day trading volumes of about 926.84K shares.